Alzheimer's Therapeutics Market on Upward Trajectory Across the 7MM During the Forecast Period (2025–2034) Fueled by Drug Development Advances | DelveInsight

New York, USA, July 08, 2025 (GLOBE NEWSWIRE) --Alzheimer's Therapeutics Market on Upward Trajectory Across the 7MM During the Forecast Period (2025–2034) Fueled by Drug Development Advances | DelveInsightThe Alzheimer's disease market is anticipated to surge owing to the expected launch of emerging therapies, such as BioVie's Bezisterim (NE3107), AB Science's Masitinib (AB1010), Annovis Bio's Buntanetap, Cassava Sciences' Simufilam (PTI-125), TauRx Therapeutics' Hydromethylthionine mesylate (TRx0237), Novo Nordisk's semaglutide (NN6535), and Eli Lilly's Remternetug (LY3372993), among others. Other therapies in the early stages of the trial are also being developed.DelveInsight'sAlzheimer's Disease Market Insightsreport includes a comprehensive understanding of current treatment practices, Alzheimer's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].Key Takeaways from the Alzheimer's Disease Market ReportAccording to DelveInsight's analysis, the Alzheimer's Disease market size was found to beUSD 5 billionin the 7MM in 2024.The United States accounted for the highest Alzheimer's Disease drug market size, approximately50%of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.DelveInsight's analysis indicates that in 2024, there were around15 milliondiagnosed prevalent cases of Alzheimer's disease and nearly100 millionprevalent cases of preclinical Alzheimer's disease across the 7MM. These numbers are expected to grow steadily throughout the forecast period from 2025 to 2034, reflecting the rising aging population and improved diagnostic capabilities.According to DelveInsight's estimates, the US had5.5 milliondiagnosed prevalent cases of agitation associated with Alzheimer's disease in 2024.Leading Alzheimer's disease companies developing emerging therapies, such asNovo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics,and others, are developing new Alzheimer's disease treatment drugs that can be available in the Alzheimer's disease market in the coming years.The promising Alzheimer's disease therapies in the pipeline includeMasitinib (AB1010), Valiltramiprosate (ALZ-801), Mirodenafil (AR1001), Levetiracetam (AGB101), Blarcamesine (ANAVEX2-73), Buntanetap (ANVS401 or posiphen), Tricaprilin (CER0001), Bezisterim (NE3107), Semaglutide (NN6535), Remternetug (LY3372993), Masupirdine (SUVN-502), COBENFY (KarXT), IGC-AD1, T3D-959, LX 1001, AXS-05 (Bupropion/Dextromethorphan), ABvac40, E2814, Hydromethylthionine Mesylate (HMTM)/TRx0237, GV1001, ACI-35.030/JNJ-2056, LOMECEL-B (laromestrocel), Pepinemab, SinaptiStim System,and others.Discover drug trials for Alzheimer's disease @Alzheimer's Disease TreatmentsAlzheimer's Disease Market DynamicsThe Alzheimer's disease market dynamics are expected to change in the coming years. Recent advances in structural and functional MRI techniques, along with biomarker assessments, have enhanced theunderstanding of anatomical and physiological brain changesin Alzheimer's disease, supporting arobust drug development pipelinethat includes a range of molecules targeting amyloid, tau abnormalities, inflammation, and synaptic dysfunction; this creates awindow of opportunity for companiesto leverage these insights to evaluatenovel, safe, and effective therapieswith convenient dosing and lower costs to improve treatment compliance and adherence.As potential therapies are being investigated for the treatment of Alzheimer's disease, it is safe to predict that the treatment space will significantly impact the Alzheimer's disease market during the forecast period. Moreover, theanticipated introduction of emerging therapieswith improved efficacy and a furtherimprovement in the diagnosis rateare expected to drive the growth of the Alzheimer's disease market in the 7MM.However, several factors may impede the growth of the Alzheimer's disease market. Drug development for the disease has been hindered by amisunderstanding of its mechanisms, inconsistent protocols relying on single-target approaches, and poor project management, all contributing tohigh failure rates, prolonged timelines, and a low conversion to marketed products; further complicating progress are the disease's variable progression,limited and costly biomarker-based diagnostic tools, especially in later stages, and growing challenges faced by traditional drug classes likeacetylcholinesterase inhibitors and NMDA receptor antagonistsdue to generic erosion.Moreover, Alzheimer's disease treatment poses asignificant economic burdenand disrupts patients' overall well-being and QOL. Furthermore, the Alzheimer's disease market growth may be offset byfailures and discontinuation of emerging therapies,unaffordable pricing,market access and reimbursement issues, and ashortage of healthcare specialists. In addition, theundiagnosed, unreported cases and the unawarenessabout the disease may also impact the Alzheimer's disease market growth.Alzheimer's Disease Treatment MarketAlzheimer's disease currently has no known cure. However, early diagnosis and consistent treatment play a crucial role in alleviating clinical symptoms. Detecting the disease in its initial stages allows for timely symptomatic treatment, better management of behavioral symptoms, and the adoption of lifestyle interventions that may help reduce the risk of dementia and slow the progression of the disease.Most existing dementia treatments aim to manage symptoms by modulating neurotransmitter activity in the brain. These therapies typically enhance the function of neurotransmitters like acetylcholine, serotonin, and noradrenaline, or inhibit the activity of others such as glutamate and dopamine. Given the potential for adverse effects, treatment plans must be tailored to each patient, taking into account existing health conditions and possible drug interactions, particularly those affecting heart function and drug metabolism. For over a decade, medications such asacetylcholinesterase inhibitors (AChEIs) and memantine, an NMDA receptor antagonist, have been available in the U.S. for symptomatic relief.In recent years, significant progress in Alzheimer's research has led to a better understanding of disease mechanisms and the identification of new therapeutic targets. In July 2023, the U.S. FDA approvedLEQEMBI (lecanemab), developed byBiogen and Eisai, for the treatment of early-stage Alzheimer's, including mild cognitive impairment and mild dementia. The drug was subsequently approved in Japan in September 2023 and received marketing authorization in the UK in August 2024, highlighting the diverse regulatory landscape across regions. Another breakthrough came withEli Lilly's KISUNLA (donanemab), which received U.S. FDA approval in July 2024 and is considered a major advancement in treating early-stage Alzheimer's disease.To know more about FDA-approved Alzheimer's disease drugs 2025, visit @Alzheimer's Disease Treatment ResearchAlzheimer's Disease Pipeline Therapies and Key CompaniesThe Alzheimer's disease pipeline is burgeoning, with a range of global companies advancing therapies for this indication. Prominent players in the market includeAB Science(Masitinib),BioVie(Bezisterim),Annovis Bio(Buntanetap),TauRx Therapeutics(Hydromethylthionine mesylate),Cassava Sciences(Simufilam),Eli Lilly and Company(Remternetug),Novo Nordisk(Semaglutide),Eisai(E2814),UCB Pharma(Bepranemab), andGemVax & KAEL(GV1001), among others.BioVie's NE3107is an orally administered, small molecule that can cross the blood-brain barrier. It acts as an anti-inflammatory and insulin sensitizer by binding to extracellular signal-regulated kinase (ERK) and selectively suppressing inflammation. NE3107 blocks ERK/NFκB activation and reduces TNF production triggered by inflammatory agents like lipopolysaccharide. BioVie is also developing NE3107 for Parkinson's disease, multiple myeloma, and prostate cancer.Recently, the company shared Phase III trial results, where the primary efficacy endpoint did not achieve statistical significance due to patient exclusions. However, the trial's adaptive design enables continued enrollment to potentially reach statistical significance for regulatory approval. Given the efficacy signals observed, BioVie plans to collaborate with the FDA and aims for a global launch by 2026.AB Science's Masitinib (AB1010)is an oral tyrosine kinase inhibitor that targets activated mast cells and microglia, neuroimmune cells implicated in Alzheimer's disease, which can accumulate in the CNS at therapeutic levels. Evidence from a Phase II trial suggests masitinib may benefit patients with mild-to-moderate Alzheimer's disease. A confirmatory Phase III study is currently in progress.Buntanetap(formerly ANVS401 or posiphen) is a synthetically derived, orally bioavailable small molecule that functions as a Translational Inhibitor of Neurotoxic Aggregating Proteins (TINAPs). This unique mechanism offers a novel therapeutic approach for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Alzheimer's associated with Down syndrome.In February 2025, the company announced the initiation of its pivotal Phase III trial for early-stage Alzheimer's. Following a successful End-of-Phase II meeting with the FDA in October 2024, Annovis Bio received clearance to move forward with Phase III trials. The FDA and the company have agreed on a development path that supports the submission of two NDAs: one for short-term and another for long-term efficacy.Novo Nordisk's Semaglutide (NN6535)is a once-daily GLP-1 receptor agonist being studied for Alzheimer's disease. GLP-1 is a known neurotransmitter, and its receptors are found in various brain regions, including the striatum, hippocampus, and nucleus accumbens.Semaglutide is thought to slow disease progression by reducing neuroinflammation and improving cellular, neural, and vascular function, potentially enhancing cognition and daily function through diverse biological pathways. The drug is currently under evaluation in two Phase III clinical trials, EVOKE and EVOKE+, in patients with early Alzheimer's, both expected to complete in 2025.The anticipated launch of these emerging therapies are poised to transform the Alzheimer's disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Alzheimer's disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.Discover more about Alzheimer's disease drug development pipeline @Alzheimer's Disease Drug Development Pipeline 2025Recent Developments in the Alzheimer's Disease MarketInJune 2025, INmune Bio Inc.reported results from its Phase 2 MINDFuL trial (NCT05318976), which assessed XPro™, a targeted soluble TNF inhibitor, in patients with early-stage Alzheimer's disease showing signs of inflammation through biomarkers.InJune 2025, Eli Lilly and Companyannounced that the FDA had approved a label update for Amyvid (florbetapir F 18 injection), which is administered intravenously. Amyvid is utilized in brain imaging to assess the density of amyloid plaques in individuals with cognitive impairment being evaluated for Alzheimer's disease or other causes of cognitive decline.InJune 2025, InMed Pharmaceuticals Inc.reported new preclinical findings showing that INM-901 significantly reduces inflammation in ex vivo neuroinflammation models, reinforcing its promise as a potential treatment for Alzheimer's disease.InApril 2025, Biogen Inc.announced that the FDA granted Fast Track designation to BIIB080, an antisense oligonucleotide therapy targeting tau, for Alzheimer's disease treatment, aiming to speed up its development and review.InFebruary 2025, Annovis Bioreported the enrollment of the first patients in its pivotal Phase III clinical trial evaluating buntanetap for the treatment of early-stage Alzheimer's disease.InFebruary 2025, NKGen Biotech, Inc.received Fast Track designation from the FDA for its investigational drug, troculeucel, aimed at treating moderate Alzheimer's disease (AD).Alzheimer's Disease OverviewAlzheimer's disease is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behavior. It is the most common cause of dementia, especially in older adults, and is characterized by the gradual loss of neurons and the connections between them in the brain.The disease typically begins with mild memory loss but advances over time to severe cognitive impairment, disorientation, mood changes, and difficulties in performing everyday tasks. As the condition progresses, patients often lose the ability to carry out even basic bodily functions, eventually leading to death.The exact causes of Alzheimer's are not fully understood, but it is believed to result from a combination of genetic, environmental, and lifestyle factors. Key pathological features include the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain.Alzheimer's disease symptoms often start with forgetfulness, confusion, trouble with language or problem-solving, and mood or personality changes. Diagnosis involves a comprehensive assessment that includes medical history, cognitive testing, neurological exams, and imaging techniques such as MRI or PET scans. In some cases, biomarker tests using cerebrospinal fluid or blood may support the diagnosis, although these are not yet widely used in routine clinical practice.Alzheimer's Disease Epidemiology SegmentationThe Alzheimer's disease epidemiology section provides insights into the historical and current Alzheimer's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.TheAlzheimer's disease market reportproffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:Diagnosed Prevalent Cases of Alzheimer's DiseasePrevalent Cases of Preclinical Alzheimer's DiseaseAge-specific Diagnosed Prevalent Cases of Alzheimer's DiseaseGender-specific Diagnosed Prevalent Cases of Alzheimer's DiseaseSeverity-specific Diagnosed Prevalent Cases of Alzheimer's DiseaseGenotype-specific Diagnosed Prevalent Cases of Alzheimer's DiseaseDiagnosed Prevalent Cases of Agitation in Alzheimer's DiseaseDiagnosed Prevalent Cases of Psychosis in Alzheimer's DiseaseAlzheimer's Disease Market Report MetricsDetailsStudy Period2020–2034Coverage7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].Alzheimer's Disease Market Size in 2024USD 5 BillionKey Alzheimer's Disease CompaniesNovo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, Alpha Cognition, Biogen, Otsuka Pharmaceutical, Lundbeck, and othersKey Alzheimer's Disease TherapiesMasitinib (AB1010), Valiltramiprosate (ALZ-801), Mirodenafil (AR1001), Levetiracetam (AGB101), Blarcamesine (ANAVEX2-73), Buntanetap (ANVS401 or posiphen), Tricaprilin (CER0001), Bezisterim (NE3107), Semaglutide (NN6535), Remternetug (LY3372993), Masupirdine (SUVN-502), COBENFY (KarXT), IGC-AD1, T3D-959, LX 1001, AXS-05 (Bupropion/Dextromethorphan), ABvac40, E2814, Hydromethylthionine Mesylate (HMTM)/TRx0237, GV1001, ACI-35.030/JNJ-2056, LOMECEL-B (laromestrocel), Pepinemab, SinaptiStim System, ZUNVEYL, LEQEMBI, KISUNLA, REXULTI, and othersScope of theAlzheimer's DiseaseMarket ReportTherapeutic Assessment:Alzheimer's Disease current marketed and emerging therapiesAlzheimer's DiseaseMarket Dynamics:Key Market Forecast Assumptions of Emerging Alzheimer's Disease Drugs and Market OutlookCompetitive Intelligence Analysis:SWOT analysis and Market entry strategiesUnmet Needs, KOL's views, Analyst's views, Alzheimer's Disease Market Access and ReimbursementDownload the report to understand Alzheimer's disease clinical trials and drug development @Alzheimer's Disease Diagnostics and Therapeutics MarketTable of Contents1.Alzheimer's Disease Market Key Insights2.Alzheimer's Disease Market Report Introduction3.Alzheimer's Disease Market Overview at a Glance4.Alzheimer's Disease Market Executive Summary5.Disease Background and Overview6.Alzheimer's Disease Treatment and Management7.Alzheimer's Disease Epidemiology and Patient Population8.Patient Journey9.Alzheimer's Disease Marketed Drugs10.Alzheimer's Disease Emerging Drugs11.Seven Major Alzheimer's Disease Market Analysis12.Alzheimer's Disease Market Outlook13.Potential of Current and Emerging Therapies14.KOL Views15.Unmet Needs16.SWOT Analysis17.Appendix18.DelveInsight Capabilities19.Disclaimer20.About DelveInsightRelated ReportsAlzheimer's Disease PipelineAlzheimer's Disease Pipeline Insight – 2024report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer's Disease companies, includingBiogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc.,among others.Agitation in Alzheimer's Disease MarketAgitation in Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key agitation in Alzheimer's disease companies, includingEli Lilly and Co, BioVie Inc., AB Science SA, Annovis Bio Inc., Cognition Therapeutics Inc., Coya Therapeutics Inc., Actinogen Medical Limited, AC Immune SA, Biogen Inc., Longeveron Inc.,among others.Psychosis in Parkinson's and Alzheimer's Disease MarketPsychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, includingSunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme,among others.Parkinson's Disease MarketParkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, includingUCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC,among others.Alzheimer's Disease Diagnostic MarketAlzheimer's Disease Diagnostic Market Insights, Competitive Landscape and Market Forecast – 2032report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Alzheimer's disease diagnostic companies, includingF. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN™, FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, among others.DelveInsight'sPharma Competitive Intelligence Service:Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.Other Business Pharmaceutical Consulting ServicesHealthcare Conference CoveragePipeline AssessmentHealthcare Licensing ServicesDiscover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading ourDue Diligence Case StudyAbout DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.Connect with us onLinkedIn|Facebook|TwitterContact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.comLoading...Loading...Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .Posted In:Health CareAnalyst RatingsPress Releases